Business
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights
Clinical test volume surged 41% in Q4 over Q3 to 6,183 tests; full year volume of 16,233 tests outperforms initial 2025 projections Strong cash position of
About this update from Personalis, Inc.
[{"type":"text","content":"\n\nClinical test volume surged 41% in Q4 over Q3 to 6,183 tests; full year volume of 16,233 tests outperforms initial 2025 projections\n\n\n\nStrong cash position of approximately $240 million provides capital for commercial expansion\n\n\n\nSecured pivotal Medicare coverage for breast cancer surveillance, validating ultrasensitive MRD technology\n\n\n\nPreliminary Q4 revenue of $17 to $18 million; preliminary full year revenue of $69 to $70 million\n\n\n\n FREMONT, Calif.--(BUSINESS WIRE)--\nPersonalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported certain unaudited preliminary financial and operational results for the fourth quarter and full year ended December 31, 2025.\n\n\nFourth Quarter Strategic and Operational Highlights\n\n\n\nSecured Milestone Medicare Coverage: Received Medicare coverage approval for the surveillance of cancer recurrence in breast cancer patients, a key catalyst for clinical revenue and market share growth in the MRD space.\n\n\n\nPublished Landmark TRACERx Data: Announced the publication of one of the largest and most comprehensive non-small cell lung cancer (NSCLC) patient cohorts to date in the journal Cell, demonstrating the clinical importance of Personalis’ ultrasensitive MRD approach.\n\n\n\nValidation of ctDNA Dynamics: Published VHIO data in Clinical Cancer Research titled \"Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy,\" further reinforcing the clinical validity the NeXT Personal platform in a broad array of cancer types.\n\n\n\nPreliminary Full Year 2025 Financial Results\n\n\n\nTotal Revenue: Expected to be in the range of $69.0 to $70.0 million compared with $84.6 million for 2024.\n\n\n\nClinical Momentum: Clinical test revenue reached approximately $2.0 million, more than doubling the $0.8 million reported in 2024.\n\n\n\nVolume Outperformance: Clinical test volume reached approximately 16,233 tests, a nearly 400% increase over the 3,285 tests delivered in 2024. This performance exceeded the company’s internal growth targets by more than 20% and signals a significant shift in market adoption for ultrasensitive MRD testing.\n\n\n\nCore Revenue Streams: Pharma tests, services, and all other customers contributed approximately $49.0 million to $50.0 million. Revenue from enterprise sal...